Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1
Public ClinicalTrials.gov record NCT02707861. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Ibalizumab is a monoclonal antibody that works by blocking HIV entry into the immune system cells (CD4+ or T-cells) the virus typically infects. Ibalizumab is intended for use in combination with other anti-HIV drugs in people with multi-drug resistant HIV and limited treatment options. This study will collect further information on the safety and tolerability of intravenously administered (IV) ibalizumab combined with an optimized background regimen for treating multi-drug resistant HIV-1 infection, and will provide continuing access to ibalizumab for patients completing a prior ibalizumab clinical trial.
Study identification
- NCT ID
- NCT02707861
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 79 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2016 (Type not available)
- Primary completion
- Nov 2018 (Actual)
- Completion
- Nov 2018 (Actual)
- Last update posted
- Mar 11, 2021
2016 – 2018
United States locations
- U.S. sites
- 31
- U.S. states
- 15
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Long Beach Education and Research Consultants | Long Beach | California | 90813 | — |
| Southern California Permanente Medical Group | Los Angeles | California | 90027 | — |
| Ruane Clinical Research Institute Inc. | Los Angeles | California | 90036 | — |
| Charles R. Drew University of Medicine and Science, Clinical and Translational Research Center | Los Angeles | California | 90059 | — |
| Anthony Mills MD Inc. | Los Angeles | California | 90069 | — |
| Palmtree Clinical Research, Inc. | Palm Springs | California | 92262 | — |
| eStudy Site | San Francisco | California | 94115 | — |
| Kaiser Foundation Research Institute | San Francisco | California | 94118 | — |
| Yale University | New Haven | Connecticut | 06510 | — |
| Georgetown University School of Medicine | Washington D.C. | District of Columbia | 20007 | — |
| Gary Richmond, MD, PA | Fort Lauderdale | Florida | 33316 | — |
| AIDS Healthcare Foundation - Kinder Medical Group | Miami | Florida | 33133 | — |
| AIDS Healthcare Foundation - South Beach | Miami | Florida | 33140 | — |
| Orlando Immunology Center | Orlando | Florida | 32803 | — |
| Triple O Research Institute | West Palm Beach | Florida | 33401 | — |
| AIDS Research Consortium of Atlanta | Atlanta | Georgia | 30312 | — |
| University of Hawaii - John A. Burns School of Medicine | Honolulu | Hawaii | 96813 | — |
| Howard Brown Health Center | Chicago | Illinois | 60613 | — |
| National Institute of Allergy & Infectious Diseases | Bethesda | Maryland | 20892 | — |
| ID Research Institute | Springfield | Massachusetts | 01105 | — |
| Central West Clinical Research | St Louis | Missouri | 63108 | — |
| AIDS Healthcare Foundation - Manhattan Midtown HCC | New York | New York | 10001 | — |
| Chelsea Village Medical | New York | New York | 10011 | — |
| Jacobi Medical Center | The Bronx | New York | 10461 | — |
| East Carolina University | Greenville | North Carolina | 27834 | — |
| Philadelphia FIGHT | Philadelphia | Pennsylvania | 19107 | — |
| St. Jude's Children's Research Hospital | Memphis | Tennessee | 38105 | — |
| St. Hope Foundation Community Health Center | Bellaire | Texas | 77401 | — |
| North Texas Infectious Disease Consultants | Dallas | Texas | 75246 | — |
| Crofoot Research Center | Houston | Texas | 77098 | — |
| Research Access Network | Houston | Texas | 77098 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02707861, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 11, 2021 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02707861 live on ClinicalTrials.gov.